Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25478279 | 0.84 | ADRB2 (0.36) | ADRB2ADRB1ADRB3ACHEBACE1 | |
| SCHEMBL24005468 | 0.84 | ACHE (0.38) | ADRB2ADRB1ADRB3ACHECNR1 | |
| SCHEMBL25628790 | 0.81 | KCNA5 (0.31) | — | |
| SCHEMBL25613519 | 0.80 | ACHE (0.35) | ADRB2ADRB1ADRB3ACHE | |
| SCHEMBL4095123 | 0.80 | DRD2 (0.40) | MAPT | |
| SCHEMBL2603317 | 0.78 | PIK3C3 (0.41) | BACE1 | |
| SCHEMBL18913836 | 0.78 | PIK3C3 (0.41) | BACE1 | |
| SCHEMBL22213815 | 0.78 | PIK3C3 (0.41) | BACE1 | |
| SCHEMBL24775488 | 0.77 | CHRNA7 (0.38) | — | |
| SCHEMBL24775445 | 0.76 | PARP1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | ADRB2 3492/4885ADRB1 4352/4885ADRB3 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.